Scripps, Sanofi Personalized Medicine Pact to Focus Initial PGx Research on Diabetes, Aging

"We are concentrating on two initial areas — diabetes and aging research," Eric Topol, chief academic officer of Scripps Health, said. "Diabetes PGx work is of vital interest to Scripps, Sanofi, and the public."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.